Direct accesses

  • Go to main menu
  • Go to main content
Menu
GenSight GenSight
Search the site
  • Contact
  • Careers
  • You are viewing the website in English en
  • fr
Search the site
  • Whowe are
    • Company
    • Leadership
    • Collaborations
  • Diseaseswe target
    • Diseases we target
    • Leber Hereditary Optic Neuropathy (LHON)
    • Retinitis Pigmentosa (RP)
    • Geographic Atrophy in Dry-AMD
  • Ourtechnologies
    • Technologies we are applying
    • Gene Therapy
    • Mitochondrial Targeting Sequence (MTS)
    • Optogenetics
    • Clinical development Summary
  • Investors
    • Company Overview
    • Financial press releases
    • Investor Newsletters
    • Events & presentations
    • Stock information & Financial agenda
    • Governance
    • Documentation
  • Media

Documentation

  • Home >
  • Investors & media >
  • Documentation
28 April 2026
General meetings

Statutory auditors’ report on the issuance of share subscription warrants (BSA), subscription and/or acquisition warrants for new and/or existing shares (BSAANE), and/or redeemable subscription and/or acquisition warrants for new and/or existing shares (BSAAR), with cancellation of preferential subscription rights (FR) Open in new window

28 April 2026
General meetings

Statutory auditors’ report on the issuance of shares and various securities with maintenance and/or cancellation of preferential subscription rights (FR) Open in new window

28 April 2026
General meetings

Statutory auditors’ report on the capital reduction (FR) Open in new window

28 April 2026
General meetings

Statutory auditors’ certificate on the information provided pursuant to Article L. 225-115 4° of the French Commercial Code relating to the total amount of remuneration paid to the highest-paid individuals for the financial year ended December 31, 2025 (FR) Open in new window

16 April 2026
General Assembly, General meetings

Shares and voting rights statement – 2026 General Meeting Open in new window

16 April 2026
General meetings

Notice of the 2026 General Meeting Open in new window

15 April 2026
Financial statements and reports, General Assembly, Regulated information

URD 2025 Open in new window

10 March 2026
Regulated information

ANNEX IX MARCH 2026 Open in new window

01 February 2026
Regulated information

H2 2025 Liquidity Contract Report Open in new window

29 January 2026
Investor newsletter

INVESTOR NEWSLETTER – JANUARY 2026 (ENGLISH) Open in new window

  • View previous 9 articles
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • …
  • 27
  • View next 9 articles
© 2026 Gensight Biologics
  • Terms of use
  • Sitemap
  • Contact
  • Credits
  • Cookies management
Go back to the page of the page